Azenta, Inc. $AZTA Shares Purchased by Capital Fund Management S.A.

Key Points

• Capital Fund Management S.A. increased its stake in Azenta, Inc. by 31.4%, holding approximately 0.25% of the company worth about $3.89 million.
• Azenta's stock currently holds a consensus target price of $35.75, with ratings including two "Buy" and three "Hold" from analysts.
• The company reported earnings of $0.19 per share, surpassing expectations and representing a revenue of $143.94 million for the last quarter.

Capital Fund Management S.A. grew its stake in shares of Azenta, Inc. (NASDAQ:AZTA - Free Report) by 31.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 112,261 shares of the company's stock after purchasing an additional 26,813 shares during the period. Capital Fund Management S.A. owned approximately 0.25% of Azenta worth $3,889,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new position in Azenta in the 4th quarter valued at about $2,331,000. CANADA LIFE ASSURANCE Co raised its stake in Azenta by 13.5% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 43,554 shares of the company's stock valued at $2,178,000 after purchasing an additional 5,182 shares during the last quarter. First Trust Advisors LP acquired a new position in Azenta in the 4th quarter valued at about $1,034,000. Price T Rowe Associates Inc. MD raised its stake in Azenta by 4.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 31,850 shares of the company's stock valued at $1,593,000 after purchasing an additional 1,356 shares during the last quarter. Finally, Syon Capital LLC acquired a new position in shares of Azenta during the 4th quarter valued at about $359,000. 99.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on AZTA. Needham & Company LLC dropped their price objective on shares of Azenta from $59.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Raymond James Financial upgraded Azenta from a "market perform" rating to an "outperform" rating and set a $35.00 target price for the company in a report on Wednesday, August 6th. Evercore ISI set a $33.00 target price on Azenta and gave the stock an "in-line" rating in a report on Tuesday, August 5th. Finally, Stephens began coverage on Azenta in a report on Tuesday, July 22nd. They set an "equal weight" rating and a $35.00 target price for the company. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Azenta currently has a consensus rating of "Hold" and a consensus target price of $35.75.

Azenta Stock Up 1.3%

Shares of Azenta stock traded up $0.38 on Friday, hitting $30.30. 58,406 shares of the company's stock traded hands, compared to its average volume of 755,386. The stock has a market cap of $1.39 billion, a P/E ratio of -12.45 and a beta of 1.59. The firm's 50-day moving average is $31.35 and its 200 day moving average is $32.26. Azenta, Inc. has a 52-week low of $23.91 and a 52-week high of $55.63.

Azenta (NASDAQ:AZTA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.06. The business had revenue of $143.94 million for the quarter, compared to analyst estimates of $149.64 million. Azenta had a positive return on equity of 1.35% and a negative net margin of 18.45%.The business's revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.14 EPS. Equities research analysts forecast that Azenta, Inc. will post 0.53 EPS for the current year.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.